Xuan Marian Thai

Array ( [id] => 6080133 [patent_doc_number] => 20110142849 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-06-16 [patent_title] => 'PCSK9 ANTAGONISTS' [patent_app_type] => utility [patent_app_number] => 12/965743 [patent_app_country] => US [patent_app_date] => 2010-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 27848 [patent_no_of_claims] => 50 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0142/20110142849.pdf [firstpage_image] =>[orig_patent_app_number] => 12965743 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6118576 [patent_doc_number] => 20110076249 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-03-31 [patent_title] => 'IMMUNOTHERAPY FOR IMMUNE SUPPRESSED PATIENTS' [patent_app_type] => utility [patent_app_number] => 12/960130 [patent_app_country] => US [patent_app_date] => 2010-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 21508 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0076/20110076249.pdf [firstpage_image] =>[orig_patent_app_number] => 12960130 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8675687 [patent_doc_number] => 08383801 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-02-26 [patent_title] => 'Polynucleotide encoding a sclerostin-binding antibody' [patent_app_type] => utility [patent_app_number] => 12/950094 [patent_app_country] => US [patent_app_date] => 2010-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 52104 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12950094 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5945111 [patent_doc_number] => 20110105731 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-05-05 [patent_title] => 'Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon' [patent_app_type] => utility [patent_app_number] => 12/927372 [patent_app_country] => US [patent_app_date] => 2010-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 60964 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0105/20110105731.pdf [firstpage_image] =>[orig_patent_app_number] => 12927372 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9648814 [patent_doc_number] => 08802827 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-08-12 [patent_title] => 'AX1 PCSK9 antagonists' [patent_app_type] => utility [patent_app_number] => 13/503726 [patent_app_country] => US [patent_app_date] => 2010-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 38832 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 152 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13503726 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8358651 [patent_doc_number] => 20120213794 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-08-23 [patent_title] => 'AX213 AND AX132 PSCK9 ANTAGONISTS AND VARIANTS' [patent_app_type] => utility [patent_app_number] => 13/503729 [patent_app_country] => US [patent_app_date] => 2010-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 170855 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 12 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13503729 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9099818 [patent_doc_number] => 08563696 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-10-22 [patent_title] => 'Antibody specifically binding to c-Met' [patent_app_type] => utility [patent_app_number] => 12/907604 [patent_app_country] => US [patent_app_date] => 2010-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 11094 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12907604 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6195533 [patent_doc_number] => 20110027287 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-02-03 [patent_title] => 'ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9)' [patent_app_type] => utility [patent_app_number] => 12/903084 [patent_app_country] => US [patent_app_date] => 2010-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 152 [patent_figures_cnt] => 152 [patent_no_of_words] => 72928 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0027/20110027287.pdf [firstpage_image] =>[orig_patent_app_number] => 12903084 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8370165 [patent_doc_number] => 20120219558 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-08-30 [patent_title] => 'ANTAGONISTS OF PCSK9' [patent_app_type] => utility [patent_app_number] => 13/497663 [patent_app_country] => US [patent_app_date] => 2010-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 3111 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13497663 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6212273 [patent_doc_number] => 20110135573 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-06-09 [patent_title] => 'METALLOPROTEINASE 9 AND METALLOPROTEINASE 2 BINDING PROTEINS' [patent_app_type] => utility [patent_app_number] => 12/874544 [patent_app_country] => US [patent_app_date] => 2010-09-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 96148 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0135/20110135573.pdf [firstpage_image] =>[orig_patent_app_number] => 12874544 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6142220 [patent_doc_number] => 20110129481 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-06-02 [patent_title] => 'Antibody specifically binding to c-Met and methods of use' [patent_app_type] => utility [patent_app_number] => 12/807191 [patent_app_country] => US [patent_app_date] => 2010-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 12675 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0129/20110129481.pdf [firstpage_image] =>[orig_patent_app_number] => 12807191 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6142220 [patent_doc_number] => 20110129481 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-06-02 [patent_title] => 'Antibody specifically binding to c-Met and methods of use' [patent_app_type] => utility [patent_app_number] => 12/807191 [patent_app_country] => US [patent_app_date] => 2010-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 12675 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0129/20110129481.pdf [firstpage_image] =>[orig_patent_app_number] => 12807191 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6142220 [patent_doc_number] => 20110129481 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-06-02 [patent_title] => 'Antibody specifically binding to c-Met and methods of use' [patent_app_type] => utility [patent_app_number] => 12/807191 [patent_app_country] => US [patent_app_date] => 2010-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 12675 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0129/20110129481.pdf [firstpage_image] =>[orig_patent_app_number] => 12807191 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6142220 [patent_doc_number] => 20110129481 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-06-02 [patent_title] => 'Antibody specifically binding to c-Met and methods of use' [patent_app_type] => utility [patent_app_number] => 12/807191 [patent_app_country] => US [patent_app_date] => 2010-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 12675 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0129/20110129481.pdf [firstpage_image] =>[orig_patent_app_number] => 12807191 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5928912 [patent_doc_number] => 20110038871 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-02-17 [patent_title] => 'CCR2 INHIBITORS FOR TREATING CONDITIONS OF THE EYE' [patent_app_type] => utility [patent_app_number] => 12/853765 [patent_app_country] => US [patent_app_date] => 2010-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21066 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0038/20110038871.pdf [firstpage_image] =>[orig_patent_app_number] => 12853765 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6110293 [patent_doc_number] => 20110189181 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-08-04 [patent_title] => 'Use of agents derived from CEACAM1 for the treatment of inflammatory diseases' [patent_app_type] => utility [patent_app_number] => 12/806002 [patent_app_country] => US [patent_app_date] => 2010-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 8621 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0189/20110189181.pdf [firstpage_image] =>[orig_patent_app_number] => 12806002 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6134964 [patent_doc_number] => 20110008789 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-01-13 [patent_title] => 'METHODS AND MATERIALS FOR TREATING INFLAMMATORY CONDITIONS' [patent_app_type] => utility [patent_app_number] => 12/833773 [patent_app_country] => US [patent_app_date] => 2010-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 27 [patent_no_of_words] => 21189 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0008/20110008789.pdf [firstpage_image] =>[orig_patent_app_number] => 12833773 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7650890 [patent_doc_number] => 20110300159 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-12-08 [patent_title] => 'Sulfonated Sclerostin, antibodies, epitopes and methods for identification and use therefor' [patent_app_type] => utility [patent_app_number] => 12/802447 [patent_app_country] => US [patent_app_date] => 2010-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 10143 [patent_no_of_claims] => 130 [patent_no_of_ind_claims] => 19 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0300/20110300159.pdf [firstpage_image] =>[orig_patent_app_number] => 12802447 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6613649 [patent_doc_number] => 20100310469 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-12-09 [patent_title] => 'VACCINE IMMUNOTHERAPY FOR IMMUNE SUPPRESSED PATIENTS' [patent_app_type] => utility [patent_app_number] => 12/475957 [patent_app_country] => US [patent_app_date] => 2010-05-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 15827 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 16 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0310/20100310469.pdf [firstpage_image] =>[orig_patent_app_number] => 12475957 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6134460 [patent_doc_number] => 20110008362 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-01-13 [patent_title] => 'ANTI-GLUTEN EGG YOLK ANTIBODIES FOR THE TREATMENT OF CELIAC DISEASE' [patent_app_type] => utility [patent_app_number] => 12/779622 [patent_app_country] => US [patent_app_date] => 2010-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 6404 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0008/20110008362.pdf [firstpage_image] =>[orig_patent_app_number] => 12779622 [rel_patent_id] =>[rel_patent_doc_number] =>)